NEW YORK, Feb. 12, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of GW Pharmaceuticals plc (“GW Pharmaceuticals”) (NASDAQ:GWPH) between December 4, 2014 and January 8, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to: http://zlk.9nl.com/gw-pharmaceuticals.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company lacked effective internal financial controls; (ii) the Company lacked effective controls over completeness and valuation of clinical trial accruals; and (iii) as a result of the foregoing, Defendants’ statements about GW Pharmaceuticals’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
In its 2015 Annual Report, GW Pharmaceuticals disclosed the discovery of a material weakness in its internal control over financial reporting for the year ended September 30, 2015. The Company noted that “management does not have sufficiently precise controls to evaluate the completeness and accuracy of the calculation of clinical trial accruals due to the incorrect allocation of expenditure to clinical studies.” On this news, GW Pharmaceuticals stock fell $3.55, or nearly 6%, to close at $56.31 per share on January 11, 2016.
If you suffered a loss in GW Pharmaceuticals you have until March 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/gw-pharmaceuticals.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
OpenAI Explores Massive Funding Round at $750 Billion Valuation
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 



